Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Current assets
Cash and cash equivalents	$ 11,780	$ 10,537
Prepaid expenses, deposits and other	1,478	756
Clinical trial deposit		500
Total current assets	13,258	11,793
Clinical trial deposit	2,600	1,600
Property, equipment and intangibles - net	90	150
Total assets	15,948	13,543
Current liabilities
Accounts payable and accrued liabilities	3,269	2,219
Related party payables	721	561
Total current liabilities	3,990	2,780
Milestone payment liability	163	182
Total liabilities	4,153	2,962
Stockholders’ equity
Common stock Authorized 275,000 shares at June 30, 2022 (June 30, 2021 - 175,000), $0.001 par value Issued and outstanding 65,533 issued at June 30, 2022 (June 30, 2021 32,740)	66	33
Additional paid-in capital	135,510	106,821
Accumulated deficit	(136,356)	(111,225)
Accumulated other comprehensive income	21	21
Total stockholders’ equity	11,795	10,581
Total liabilities and stockholders’ equity	15,948	13,543
Preferred Stock Series A
Stockholders’ equity
Preferred stock	279	279
Preferred Stock Series C
Stockholders’ equity
Preferred stock	$ 12,275	$ 14,652